---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109295"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:29:05.232481+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics appoints Michael Nofi as CFO, succeeding retiring CFO Carruthers

## Summary
- Michael Nofi appointed CFO effective Nov 10, 2025; replaces R. Michael Carruthers who retired.
- Nofi's annual base salary: $465,000, target cash bonus 40% of salary, plus stock option for 262,500 shares and 43,750 RSUs.
- Carruthers to remain employee until Jan 31, 2026, then consultant through Oct 31, 2026, with continued equity vesting.
- Nofi previously Chief Accounting Officer at SpringWorks Therapeutics; brings 30+ years life sciences finance experience.
- No disagreement between Carruthers and company; transition supports Edgewise's late-stage clinical and commercialization prep.

## SEC filing metadata
- accession: 0001104659-25-109295
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925109295/0001104659-25-109295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925109295/tm2530663d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109295
- JSON: https://secwatch.observer/filing/0001104659-25-109295.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.